Studies assessing the combination of anti-PD-1 in conjunction with anti-CTLA-4, with BRAF inhibitors, as well as, anti-VEGF agents are ongoing particularly for patients with advanced thyroid cancer aiming to improve response to anti-PD-1 therapy (49, 50). This evidence concerns the gene PDCD1 and thyroid cancer.